Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index …………… Shen W, De Hoyos CL, Migawa MT, Vickers TA, Sun H, Low A, Bell TA 3rd, Rahdar M, Mukhopadhyay S, Hart CE, Bell M, Riney S, Murray SF, Greenlee S, Crooke RM, Liang XH, Seth PP, Crooke ST. Nat Biotechnol. 2019…
Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations …………… Huang L, Aghajan M, Quesenberry T, Low A, Murray SF, Monia BP, Guo S. Nucleic Acid Ther. 2019 May 9. PubMed
Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates …………… Østergaard ME, Jackson M, Low A, E Chappell A, G Lee R, Peralta RQ, Yu J, Kinberger GA, Dan A, Carty R, Tanowitz M, Anderson P, Kim TW, Fradkin L, Mullick AE, Murray S, Rigo F, Prakash…
ApoC-III ASO Promotes Tissue LPL Activity in Absence of ApoE-Mediated TRL Clearance …………… Ramms B, Patel S, Nora C, Pessentheiner AR, Chang MW, Green CR, Golden GJ, Secrest P, Krauss RM, Metallo CM, Benner C, Alexander VJ, Witztum JL, Tsimikas S, Esko JD, Gordts PLSM. J Lipid Res. 2019 May 14. PubMed